Compare PAYP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | GKOS |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.6B |
| IPO Year | 2025 | 2015 |
| Metric | PAYP | GKOS |
|---|---|---|
| Price | $16.51 | $154.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $25.54 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 710.9K | 636.1K |
| Earning Date | 08-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | $20.92 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $12.07 | $73.16 |
| 52 Week High | $24.89 | $191.62 |
| Indicator | PAYP | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 33.05 |
| Support Level | $14.47 | $145.78 |
| Resistance Level | $18.98 | $161.53 |
| Average True Range (ATR) | 0.75 | 7.06 |
| MACD | -0.20 | -2.33 |
| Stochastic Oscillator | 15.38 | 11.50 |
PayPay is a financial technology company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.